Abcam, Molecular Devices join forces to develop immunoassays for researchers

Abcam and Molecular Devices combine their technologies in a series of high-sensitivity fluorescent ELISA kits for researchers.

Abcam, a supplier of protein research material and kits, has teamed up with bioanalytical measurement solutions expert Molecular Devices to develop screening tools for the life science industry.

The initial focus of this transatlantic collaboration is on creating new high-sensitivity fluorescent enzyme-linked immunosorbent assay (ELISA) kits. These immunoassays are used to detect and quantify substances such as peptides and proteins in basic research, high throughput screening and diagnostics.

The final product, called CatchPoint SimpleStep ELISA kits, combines the speed of Adcam’s single-wash protocol that reduces assay time to 90 minutes or less with Molecular Devices’ fluorescent technology. Compared to TMB substrate, using a fluorescent substrate offers “improved linearity over an extended dynamic range [that provides] better quantification at both the lower and the upper end of the curve,” described Abcam on its website.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

“Optimized for our industry-leading plate readers, these kits will provide customers with a cohesive solution that enables better results faster,” said Scott Greenstone, Molecular Devices’ director of open innovation and reagents, in a statement.

These combined kits are sold by U.K.-based Abcam, and Greestone said the two companies will work together throughout 2018 to further expand the offering.

A November 2016 report by Markets and Markets predicted that the global immunoassay market—including for research and diagnostic purposes—will grow from about $17 billion to over $25 billion by 2021, with hospitals accounting for the largest share.


Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.